Fluzone Influenza Vaccine Descriptions 2022
Sanofi Pasteur's Fluzone Quadrivalent influenza vaccine contains the 2 strains each of influenza A and B identified for the current flu season. The Fluzone vaccine is given to people 6 months of age and older.
And the Fluzone High-Dose is a vaccine given to people 65 years of age and older that also contains 4 killed flu virus strains. Fluzone High-Dose contains four times the antigen (the part of the vaccine that helps your body build up protection against flu viruses) of standard-dose inactivated influenza vaccines. The higher dose of antigen in the vaccine is intended to give older people a better immune response and better protection against flu, says Sanofi.
For the 2021-2022 flu season in the Northern Hemisphere, the quadrivalent (four-component) egg-based vaccines protect against a second lineage of B viruses. U.S. Egg-Based influenza vaccines are recommended to contain the following A/Victoria/2570/2019 (H1N1)pdm09-like virus, A/Cambodia/e0826360/2020 (H3N2)-like virus, B/Washington/02/2019 (B/Victoria lineage)-like virus, and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
"We are experiencing fast-growing demand for our vaccine in the U.S. and globally, given the 10 years of data demonstrating protection from flu and its related complications," said Elaine O'Hara, Head of North America Commercial Operations for Sanofi Pasteur, in a related press statement issued on June 17, 2021. "Our new facility will complement our existing capacities to produce enough high-dose vaccine for all people 65 and older in as many countries as possible this flu season and beyond, supporting the needs of healthcare providers and patients."
Sanofi Pasteur produces influenza vaccines each year across five international sites: Swiftwater (Pennsylvania, United States), Pearl River (New York, United States), Val-de-Reuil, Ocoyoacac (Mexico), and Shenzhen (China). As the largest manufacturer of influenza vaccines globally, Sanofi has been continuously investing to expand manufacturing capabilities and distributed more than 250 million doses of influenza vaccines globally in 2020.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.|
Fluzone Influenza Vaccine Indication
Fluzone Quadrivalent and Fluzone High-Dose vaccines help prevent influenza disease caused by influenza A and B strains contained in each vaccine.
Fluzone Quadrivalent is approved to help protect eligible people 6 months and older. Fluzone High-Dose is specifically formulated for people 65 years and older, containing 4 times the standard dose. It’s proven to be 24.2% more effective than the standard-dose Fluzone vaccine in preventing the flu.
Fluzone Influenza Vaccine Safety Information
Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be given to anyone who has had a severe allergic reaction to any vaccine component (including eggs or egg products for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after a previous dose of the vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be given to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine.
Fluzone Influenza Vaccines and COVID-19 Vaccines
The US Centers for Disease Control and Prevention (CDC) previously issued interim clinical considerations stating that 'COVID-19 vaccines and other vaccines, including influenza vaccines, can be administered without regard to timing. And the annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications. 'Providers should be aware of the potential for increased reactogenicity with coadministration and should consult the CDC for updated guidance as more information becomes available. If coadministered, COVID-19 vaccines and vaccines that might be more likely to cause a local reaction (e.g., aIIV4 or HD-IIV4) should be administered in different limbs, if possible.'
October 20, 2021, the CDC reported on the interim results from a Phase 2 clinical trial that studies Fluzone and the third dose of Moderna COVID-19 Vaccine (SpikeVax) administered either concomitantly or singly in participants 65 Years of age and older who were previously vaccinated with a 2-dose schedule of Moderna COVID-19 vaccine. Of the 296 trial participants, the study results demonstrate that QIV-HD and mRNA-1273 vaccine (100µg) can be administered safely together without evidence of immunogenicity interference, supporting existing co-administration recommendations of COVID-19 and influenza vaccines.
Fluzone Influenza Vaccine Side Effects
Fluzone vaccines are generally well-tolerated, however, if you or your loved one has an adverse reaction to the vaccine, that information should be reported to VAERS.
VAERS is a U.S. passive reporting system, meaning it relies on individuals to send in reports of their experiences to a vaccine. Anyone can submit a report to VAERS, including parents and patients. Furthermore, healthcare providers are required by law to report to VAERS.
Fluzone Influenza Vaccine News 2020 - 2022
May 4, 2022 - For week 16, Flu News Europe reported the percentage of all sentinel primary care specimens from patients presenting with ILI or ARI symptoms that tested positive for an influenza virus decreased to 20% following a period between 25% and 30% for the prior 6 weeks.
April 8, 2022 - The CDC FluView reported so far this season, there have been at least 3.8 million flu illnesses, 38,000 hospitalizations, and 2,300 deaths from flu.
December 20, 2021 - The WHO reported data up to December 5, 2021, indicating in North America, influenza detections (predominately A(H3N2) among the subtyped) increased) but overall remained low. Additionally, RSV activity decreased in the USA and Canada.
October 16, 2021 - The 2021-22 influenza season report for week 41 indicated the ILINet continues to report below baseline cases. Of 28,629 specimens tested, 36 were positive, 17 were influenza A, while 19 were influenza B.
October 7, 2021 - In the UK indicators for influenza such as hospital admissions and GP influenza-like illness consultation rates remain very low. Week 40 reported 8 influenza positive cases.
September 11, 2021 - Influenza virus circulation remains low; therefore, increases in ILI activity are likely due to increased circulation of other respiratory viruses.
September 4, 2021 - The US CDC reported three regions (3,7 and 9) are ar or above their ILI region-specific baselines, and the remaining regions are below their region-specific baselines.
June 17, 2021 - The U.S. Food and Drug Administration Center for Biologics Evaluation and Research has approved Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility located in Swiftwater, PA.
March 8, 2021 - Certain patients have an increased risk of influenza infections and poor serologic response to standard influenza vaccination. A new study found tandem high-dose influenza vaccination leads to more robust and more durable seroprotection in high-risk patients.
October 7, 2020 - High-dose flu vaccine is in short supply in some places. If the high-dose vaccine is not available, the CDC recommends getting the regular dose.
Fluzone Influenza Vaccine Clinical Trials
Fluzone has been tested in over 150 clinical trials.